Literature DB >> 12076671

Advances in understanding of fragile X pathogenesis and FMRP function, and in identification of X linked mental retardation genes.

Barbara Bardoni1, Jean-Louis Mandel.   

Abstract

The fragile X mental retardation syndrome is caused by large methylated expansions of a CGG repeat in the FMR1 gene that lead to the loss of expression of FMRP, an RNA-binding protein. FMRP is proposed to act as a regulator of mRNA transport or translation that plays a role in synaptic maturation and function. The recent observations of unexpected phenotypes in some carriers of fragile X premutations suggest a pathological role, in these individuals, of an abnormal FMR1 mRNA. FMRP was recently shown to interact preferentially with mRNAs containing a G quartet structure. Mouse and Drosophila models are used to decipher the function of FMRP, which was found to inhibit translation of some mRNA targets, but may be stimulatory in other cases. Proteins interacting with FMRP have been identified, and suggest a link with the Rac1 GTPase pathway that is important in neuronal maturation. Recent advances also include identification of other genes implicated in X-linked mental retardation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076671     DOI: 10.1016/s0959-437x(02)00300-3

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  42 in total

1.  nev (cyfip2) is required for retinal lamination and axon guidance in the zebrafish retinotectal system.

Authors:  Andrew J Pittman; John A Gaynes; Chi-Bin Chien
Journal:  Dev Biol       Date:  2010-06-09       Impact factor: 3.582

2.  Nuclear transit of human zipcode-binding protein IMP1.

Authors:  Jacob Nielsen; Sidsel K Adolph; Ewa Rajpert-De Meyts; Jens Lykke-Andersen; Grete Koch; Jan Christiansen; Finn C Nielsen
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

Review 3.  Structures of trinucleotide repeats in human transcripts and their functional implications.

Authors:  Anna Jasinska; Gracjan Michlewski; Mateusz de Mezer; Krzysztof Sobczak; Piotr Kozlowski; Marek Napierala; Wlodzimierz J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

4.  Physiological activation of synaptic Rac>PAK (p-21 activated kinase) signaling is defective in a mouse model of fragile X syndrome.

Authors:  Lulu Y Chen; Christopher S Rex; Alex H Babayan; Eniko A Kramár; Gary Lynch; Christine M Gall; Julie C Lauterborn
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

Review 5.  Protein interactions and complexes in human microRNA biogenesis and function.

Authors:  Marjorie P Perron; Patrick Provost
Journal:  Front Biosci       Date:  2008-01-01

Review 6.  MicroRNAs in brain function and disease.

Authors:  Andreas Walter Kuss; Wei Chen
Journal:  Curr Neurol Neurosci Rep       Date:  2008-05       Impact factor: 5.081

7.  Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.

Authors:  Wenzhong William Min; Christopher J Yuskaitis; Qijiang Yan; Christopher Sikorski; Shengqiang Chen; Richard S Jope; Robert P Bauchwitz
Journal:  Neuropharmacology       Date:  2008-10-14       Impact factor: 5.250

Review 8.  Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders.

Authors:  Greg C Carlson
Journal:  Pharmacol Biochem Behav       Date:  2011-02-16       Impact factor: 3.533

9.  Does the presence of AGG interruptions within the CGG repeat tract have a protective effect on the fertility phenotype of female FMR1 premutation carriers?

Authors:  M Friedman-Gohas; M Kirshenbaum; A Michaeli; N Domniz; S Elizur; H Raanani; R Orvieto; Y Cohen
Journal:  J Assist Reprod Genet       Date:  2020-02-24       Impact factor: 3.412

10.  Biochemical evidence for the association of fragile X mental retardation protein with brain polyribosomal ribonucleoparticles.

Authors:  Edouard W Khandjian; Marc-Etienne Huot; Sandra Tremblay; Laetitia Davidovic; Rachid Mazroui; Barbara Bardoni
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.